Thursday, August 6, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary

Tag: cervical-spinal-cord-injury

3 articles

Industry News

Neuvotion launches first US commercial BCI-platform product this fall

On Monday 27 July 2026, Chad Bouton's Neuvotion announced the first US commercial launch of a product from a brain-computer interface platform. NeuStim NN-01, a wearable neuromuscular stimulator for hand recovery after stroke or C5 spinal cord injury, ships this fall. Neuvotion holds an exclusive worldwide license from the Feinstein Institutes, where Bouton is senior author of the 16 July Nature Medicine paper on the underlying double neural bypass platform. The intracortical BCI half of that platform, tested in one patient (Keith Thomas), remains investigational.

Jul 27

Industry News

Keith Thomas can feel his dog: Feinstein's three-year double neural bypass lands in Nature Medicine

On 16 July 2026, Nature Medicine put on its cover a three-year follow-up of Keith Thomas of Massapequa, New York, who was implanted with five microelectrode arrays in March 2023 as the first participant in the Feinstein Institutes' 'double neural bypass' trial. The Chad Bouton team's paper reports that Thomas can now feed himself, drink from a cup, feel touch on his right wrist, and pet his dog Bow, with strength and sensation gains persisting more than two years after the stimulation was switched off.

Jul 18

Industry News

China performs first commercial Neuracle NEO implant

On Monday 13 July 2026, neurosurgeons at Huashan Hospital affiliated with Fudan University performed the first commercial implantation of Neuracle's NEO brain-computer interface in a male patient with tetraplegia from a decade-old cervical spinal cord injury. The device is coin-sized, epidural, battery-free, and drives a pneumatic glove for hand grasping. Neuracle NEO is the world's first commercial invasive brain-computer interface implant for motor restoration in paralysis, following NMPA Class III market approval on 13 March 2026.

Jul 16